Genmab reports $3.96 billion in DARZALEX sales for first quarter 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2026
April 14, 2026 6:22 AM EDTCompany Announcement
Net sales of DARZALEX® in the first quarter of 2026 totaled USD 3,964 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN, Denmark; April 14, 2026 Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX... More
